Optical coherence tomography angiography in wet age-related macular degeneration (AMD)

Marques, João Pedro; Silva, Rufino

doi:10.21037/jes.2016.04.18

Cited by 2 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As opposed to quiescent or subclinical neovascularization, those lesions had been active and treated in the past. So, this term does not apply to naïve neovascularization and is documented in OCT-A as a skeletonized net [52,60,61].…”

Section: Drusen Volume Baseline Drusen Volumementioning

confidence: 99%

Retinal Progression Biomarkers of Early and Intermediate Age-Related Macular Degeneration

Flores

Carneiro

Tenreiro

et al. 2021

Life

View full text Add to dashboard Cite

Early and intermediate AMD patients represent a heterogeneous population with an important but variable risk of progression to more advanced stages of the disease. The five-year progression from early and intermediate AMD to late disease is known to range from 0.4% to 53%. This wide variation explains the particular interest in searching predictive AMD biomarkers. Clinical parameters such as drusen size, presence of pigmentary abnormalities, and fellow eye status were, traditionally, the more important predictive elements. Multimodal retinal assessment (Color Fundus Photography, Optical Coherence Tomography, Optical Coherence Angiography and Fundus Autofluorescence) is providing new and accurate image biomarkers, useful in research and in daily practice. If individual progression risk could be anticipated, then management plans should be adapted accordingly, considering follow-up intervals and therapeutic interventions. Here, we reviewed the most important image progression biomarkers of early and intermediate AMD with relevant interest in clinical practice.

show abstract

Section: Drusen Volume Baseline Drusen Volumementioning

confidence: 99%